ABN 53 075 582 740

ASX ANNOUNCEMENT
13 February 2014

BIONOMICS TO PRESENT MELANOMA COMPOUND AT LORNE CANCER CONFERENCE

Bionomics Limited (ASX:BNO, ADR:BMICY) will deliver a poster presentation on its novel BL-011256 compound targeting metastatic melanoma at the Lorne Cancer Conference this week.

The conference runs for three days from Thursday 13 February attracting over 400 local and international cancer researchers from hospitals, universities, research institutes and biotechnology companies. This year is the 26th instalment of the conference held in Lorne, Victoria.

Bionomics' abstract to be presented at the conference, *BL-011256 is a novel VEGFR3 selective inhibitor, which suppresses tumour lymphatics and lymph node metastasis in an animal model of melanoma,* will discuss the compound being developed through a partnership with the Co-operative Research Centre for Cancer Therapeutics.

BL-011256 is an advanced lead being developed as an inhibitor of tumour metastasis with a focus on the treatment of melanoma. Its mechanism of action operates through the inhibition of the VEGFR3 receptor, which mediates the formation of tumour lymphatic vessels that serve as conduits for tumour metastasis to lymph nodes. Approximately 90% of cancer deaths are caused due to the spread from the original site of the cancer, making mechanisms addressing metastasis a key to saving lives.

The proof of concept in an animal model was announced in May last year and found the compound proved itself effective in inhibiting tumour growth and suppressing metastasis in an animal model of melanoma. When administered orally BL-011256 attains free drug plasma levels above the concentration required for VEGFR3 inhibition. This makes it suitable for administration as a tablet. Impressive suppression of lymph node metastasis and inhibition of primary melanoma lesion growth was observed in the animal model of melanoma as shown below in the appendix.

Melanoma is the third most common form of cancer in Australian men and women, accounting for 10% of all cancer sufferers. Australia has the highest incidence of melanoma in the world with over 1,500 deaths each year. Approximately 12,500 cases of melanoma are diagnosed every year in Australia and this continues to rise with around 400 extra cases each year.

Appendix

BL011256 inhibits the growth of primary melanoma lesions (A) and suppresses tumour metastasis to the lymph nodes (B) in the B16F10 melanoma model.



(A) Primary lesions on ears from mice treated with BL-011256 showed a distinctive irregular and flatter appearance compared to vehicle treated lesions. Volume measurements show a statistically significant decrease in lesion volume compared to the vehicle treated tumours.



(B) Mice treated with BL-011256 had 50% less visible metastatic lesions in the draining lymph nodes compared to vehicle treated animals.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited
Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co and Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.